ENG/中
美国
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
抗疫概念
882.663
+33.236
3.91%
手動刷新
漲家數:
18
跌家數:
- -
平家數:
- -
市盈率:
- -
高:
886.237
開:
850.659
低:
850.659
收:
849.427
資料載入中...
總覽
新聞
復星醫藥,增持復宏漢霖至63.43%
市场资讯
·
5小時前
濟南比亞迪半導體申請圖像生成專利,保障目標圖像與用户視覺習慣匹配
金融界
·
6小時前
去年北京追回醫保基金4.64億元
美港电讯
·
6小時前
劉強東火鍋談話全文:“老兄弟”退休金不低於5000
蓝鲸新闻
·
7小時前
港股醫藥逆勢走強 港股醫藥ETF漲超3% 衝擊四連漲
东方财富证券
·
7小時前
港股概念追蹤|生物醫藥去庫存週期尾聲 原料藥+創新藥受益國產替代(附概念股)
智通财经
·
7小時前
復宏漢霖盤中漲超9% 復星醫藥擬5.17億港元增持復宏漢霖3.87%股權
新浪港股
·
7小時前
港股異動 | 復宏漢霖(02696)再漲超9% 復星醫藥擬5.17億港元增持復宏漢霖3.87%股權
智通财经
·
8小時前
【白雲山(00874.HK):明興藥業收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》】白雲山(00874.HK)發佈公告,近日,該公司子公司廣州白雲山明興製藥有限公司(以下簡稱“明興藥業”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意明興藥業核減生產範圍、生產車間和生產線。
金融界
·
8小時前
諾和諾德與京東健康開啓戰略合作,將共同打造肥胖症科普專區
新京报
·
8小時前
白雲山(00874):明興藥業收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》
智通财经网
·
8小時前
【港股醫藥股走強 歌禮制藥漲近18%】截至發稿,歌禮制藥-B(01672.HK)漲17.81%、榮昌生物(09995.HK)漲10.06%、映恩生物-B(09606.HK)漲9%、來凱生物-B(02105.HK)漲8.25%。
金融界
·
8小時前
總規模10億元中生引領基金揭牌,浦東創投、中國生物製藥等為首關出資人
美港电讯
·
8小時前
港股創新藥板塊走強,歌禮制藥(01672.HK)漲超20%,榮昌生物(09995.HK)、石藥集團(01093.HK)漲
美港电讯
·
8小時前
港股異動 | 歌禮制藥-B(01672)早盤漲超22% 禮來公佈口服降糖藥積極結果 ASC30具備更大商業化BD潛力
智通财经
·
8小時前
年內基金業績排名生變:北交所、醫藥崛起,機器人板塊退潮
环球网
·
8小時前
石藥集團盤中異動 早盤股價大漲5.04%
市场透视
·
9小時前
東陽光長江藥業盤中異動 股價大漲5.04%
市场透视
·
9小時前
歌禮制藥-B股價拉昇16.40% 市值漲8.95億港元
市场透视
·
9小時前
北京大學全球健康發展研究院院長劉國恩:分級診療任重道遠
市场资讯
·
9小時前
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1515/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":882.6631,"timestamp":1745309290509,"preClose":849.42694,"halted":0,"volume":571779316,"delay":0,"changeRate":0.039128,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":33.236145,"latestTime":"04-22 16:00:00","open":850.65875,"high":886.2366,"low":850.65875,"amount":3791149528.5,"amplitude":0.041884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"pbRate":1.548396,"peRate":20.662208,"turnoverRate":0.007583,"increases":18,"decrements":0,"flats":0,"marketCap":610485035392,"floatMarketCap":500669397888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":886.2366,"amplitude":0.041884,"preClose":849.42694,"low":850.65875,"pbRate":"1.548396","latestPrice":882.6631,"volume":571779316,"delay":0,"open":850.65875,"prevYearClose":787.97723,"prevWeekClose":849.427,"prevMonthClose":870.015,"prevQuarterClose":870.015,"fiveDayClose":840.443,"twentyDayClose":934.049,"sixtyDayClose":758.629,"secType":"PLATE","market":"HK","turnoverRate":0.007583,"peRate":20.662208,"marketCap":610485035392,"floatMarketCap":500669397888,"timestamp":1745309290509,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":18,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529124313","title":"復星醫藥,增持復宏漢霖至63.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529124313","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529124313?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:03","pubTimestamp":1745298180,"startTime":"0","endTime":"0","summary":" 复星医药发公告指,上周四斥资3.68亿港元增持复宏汉霖约1494.07万股非上市股份,平均每股作价24.6港元,卖方为生物科技投资公司HenLink。 复星医药又在4月15日与舟山果运签订股份转让协议,向对方收购138.12万股复宏汉霖非上市股份,每股代价为24.6港元,涉3397.75万港元。 上述数项交易完成后,复星医药持有复宏汉霖股权比例会由59.56%增加至63.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-04-22/doc-inetzkuw4200955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1593","BK0028","600196","02196","BK0175","02696","BK0183","BK0060","BK0096","BK0188","BK0196","BK0187","BK0239","BK1161","BK1515","BK0012"],"gpt_icon":0},{"id":"2529390545","title":"濟南比亞迪半導體申請圖像生成專利,保障目標圖像與用户視覺習慣匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2529390545","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529390545?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 12:01","pubTimestamp":1745294502,"startTime":"0","endTime":"0","summary":"金融界2025年4月22日消息,国家知识产权局信息显示,济南比亚迪半导体技术有限公司申请一项名为“图像生成方法、控制装置、电子装置、车辆及存储介质”的专利,公开号CN119854643A,申请日期为2024年8月。通过天眼查大数据分析,济南比亚迪半导体技术有限公司共对外投资了2家企业,参与招投标项目2次,专利信息45条,此外企业还拥有行政许可1个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042212130994dd9e4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042212130994dd9e4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","LU1720050803.USD","LU0979878070.USD","SG9999015945.SGD","LU1023057109.AUD","BK1610","LU0516422440.USD","LU2249611893.SGD","LU0289961442.SGD","LU1861219969.SGD","00285","BK1515","81211","LU0269904917.USD","BK1119","LU0348735423.USD","LU1719994722.HKD","LU1861214812.USD","LU2399975544.HKD","SG9999015986.USD","BK1149","LU0214875030.USD","LU0449515922.USD","002594","HYDD.SI","LU0229945570.USD","LU1880383366.USD","LU0516422952.EUR","LU0865486749.SGD","LU0143863198.USD","LU0143863784.USD","LU0315178854.USD","LU0463099449.HKD","LU0511384066.AUD","LU0593848301.USD","LU0054450605.USD","BYDDY","LU0274383008.USD","LU0348805143.USD","LU2476274308.USD","LU2360107325.USD","LU0561508036.HKD","LU0327786744.USD","LU0516422366.SGD","01211","LU2097828805.USD","BK1504","LU2097828474.EUR","LU1794554557.SGD","LU0348825331.USD"],"gpt_icon":1},{"id":"2529392335","title":"去年北京追回醫保基金4.64億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529392335","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529392335?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:47","pubTimestamp":1745293635,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK1161","159938","BK1515","09939"],"gpt_icon":0},{"id":"2529391065","title":"劉強東火鍋談話全文:“老兄弟”退休金不低於5000","url":"https://stock-news.laohu8.com/highlight/detail?id=2529391065","media":"蓝鲸新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529391065?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:15","pubTimestamp":1745291726,"startTime":"0","endTime":"0","summary":"4月21日,京东创始人刘强东在亲自参与外卖配送之后,请外卖骑手们吃海底捞火锅。吃饭期间刘强东发表讲话,谈及送外卖的感受、为骑手缴纳五险一金等内容。刘强东称:“京东这种工作稳定,五险一金全齐了。我们老兄弟干了18年,他还可以照样干五年,还没到退休年龄。20多年之后,他离开京东的时候,光公积金一项就要给二三十万现金一次性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504223384150057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0008368742.USD","BK4503","LU0140636845.USD","LU0417516902.SGD","LU1044874839.SGD","BK1247","BK1515","BK4614","LU0345776255.USD","LU0163747925.USD","LU1770034418.SGD","LU0531971595.HKD","LU0588545904.SGD","LU0543330483.HKD","09618","LU0259732245.USD","LU0228367735.SGD","LU0791591158.USD","BK1610","06618","BK4579","LU0865486749.SGD","BK4505","LU0128522157.USD","BK4509","BK1583","LU0359202008.SGD","LU0431992006.USD","LU0307460666.USD","LU1808992512.USD","LU0828237510.HKD","LU0315179316.USD","LU0051755006.USD","LU0588546209.SGD","LU0499858602.USD","LU1282649810.SGD","LU0384037296.USD","LU0417516738.SGD","LU2242644610.SGD","LU1794554557.SGD","SG9999001226.SGD","LU0326950275.SGD","89618","BK1591","LU0048580855.USD","LU1813983027.USD","LU0029875118.USD","LU1688375341.USD","JD","86618"],"gpt_icon":1},{"id":"2529391901","title":"港股醫藥逆勢走強 港股醫藥ETF漲超3% 衝擊四連漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2529391901","media":"东方财富证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529391901?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:10","pubTimestamp":1745291400,"startTime":"0","endTime":"0","summary":"4月22日,港股市场集体震荡环境下,港股医药带头领涨,港股医药ETF上涨3.10%,冲击4连涨。成分股石药集团、百济神州、信达生物、再鼎医药、康方生物上涨超 5%。港股医药ETF紧密跟踪中证港股通医药卫生综合指数,中证港股通医药卫生综合指数从港股通范围内选取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本,以反映港股通范围内医药卫生上市公司证券的整体表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004220.SGD","LU1226287529.USD","LU1152091168.USD","LU0880133367.SGD","LU1960683339.HKD","LU0501845795.SGD","LU0140636845.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","HSTECH","LU1226287875.USD","06160","LU0067412154.USD","LU0072913022.USD","LU1226288253.USD","09688","IE0008369823.USD","LU1993786604.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01093","LU1008478684.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","09926","LU1951186391.HKD","IE0008368742.USD","01801","IE00B543WZ88.USD","LU1226287792.SGD","BK1521","BK1191","LU1807302812.USD","BK1515","IE00B031HY20.USD"],"gpt_icon":1},{"id":"2529204399","title":"港股概念追蹤|生物醫藥去庫存週期尾聲 原料藥+創新藥受益國產替代(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529204399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529204399?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:50","pubTimestamp":1745290214,"startTime":"0","endTime":"0","summary":"探索建立生物医药企业进口研发用物品“白名单”制度,允许免予办理进口药品通关单。中国由于工程师红利、环保及成本优势过往承接全球原料药生产重心转移,为全球主工厂之一。期内总收入为21亿元人民币,其中产品销售收入20亿元人民币,同比增长25%。机构预期康方生物今年的产品销售将同比增长60%至33亿元人民币,受惠今年初AK104和AK112被纳入中国国家医保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287792.SGD","LU1993786604.SGD","LU0072913022.USD","399441","09995","IE0008369823.USD","06978","IE00BZ08YT58.USD","LU0501845795.SGD","HSTECH","IE0008368742.USD","IE00B031HY20.USD","LU1152091754.HKD","LU1226288253.USD","IE00B5MMRT66.SGD","LU1807302812.USD","BK1515","LU0326950275.SGD","LU0067412154.USD","01093","IE00B543WZ88.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","BK1161","LU1951186391.HKD","LU1969619763.USD","LU1226287875.USD","BK1521","LU1226287529.USD","LU2328871848.SGD","BK1574","BK1191","LU0140636845.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","BK4614","159992","LU1008478684.HKD","LU1960683339.HKD","YANG","BK1583","161726","LU1226288170.HKD"],"gpt_icon":1},{"id":"2529395970","title":"復宏漢霖盤中漲超9% 復星醫藥擬5.17億港元增持復宏漢霖3.87%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2529395970","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529395970?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:42","pubTimestamp":1745289720,"startTime":"0","endTime":"0","summary":" 复宏汉霖盘中涨超9%,截至发稿,股价上涨8.40%,现报36.80港元,成交额3593.75万港元。 消息面上,复星医药公布,今年4月11日至17日期间,控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别签订转让协议,控股子公司复星医药产业拟以24.60港元/股的价格受让上海善梧、无锡通善、舟山果运及Henlink合计持有的2103万股复宏汉霖非上市股份,转让价款共计5.17亿港元。在此次增持之后,复星医药持有复宏汉霖的股权比例将增至63.43%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzepa1054800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK0012","02696","BK1593","600196","BK0096","BK0060","BK0028","BK0188","BK1515","02196","BK0175","BK0183","BK0196","BK0239","BK0187","BK1191"],"gpt_icon":0},{"id":"2529393265","title":"港股異動 | 復宏漢霖(02696)再漲超9% 復星醫藥擬5.17億港元增持復宏漢霖3.87%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2529393265","media":"智通财经","labels":["shareholding","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529393265?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:32","pubTimestamp":1745289125,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复宏汉霖再涨超9%,截至发稿,涨8.54%,报36.85港元,成交额3528.23万港元。消息面上,复星医药公布,今年4月11日至17日期间,控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别签订转让协议,控股子公司复星医药产业拟以24.60港元/股的价格受让上海善梧、无锡通善、舟山果运及Henlink合计持有的2103万股复宏汉霖非上市股份,转让价款共计5.17亿港元。在此次增持之后,复星医药持有复宏汉霖的股权比例将增至63.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","BK0175","BK1593","BK0187","BK1161","600196","BK0060","BK0096","BK0012","02196","BK0183","BK0188","BK0196","BK0239","BK0028","02696"],"gpt_icon":0},{"id":"2529600513","title":"【白雲山(00874.HK):明興藥業收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》】白雲山(00874.HK)發佈公告,近日,該公司子公司廣州白雲山明興製藥有限公司(以下簡稱“明興藥業”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意明興藥業核減生產範圍、生產車間和生產線。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529600513","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529600513?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:08","pubTimestamp":1745287717,"startTime":"0","endTime":"0","summary":"白云山(00874.HK)发布公告,近日,该公司子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》,同意明兴药业核减生产范围、生产车间和生产线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22100849738128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600332","BK0196","BK1574","BK0239","BK0188","BK1606","BK1197","BK1515","BK1521","BK0097","BK1191","BK0183","BK0070","BK0175","BK0096","BK0028","00874","BK0012","01477"],"gpt_icon":0},{"id":"2529539359","title":"諾和諾德與京東健康開啓戰略合作,將共同打造肥胖症科普專區","url":"https://stock-news.laohu8.com/highlight/detail?id=2529539359","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529539359?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:05","pubTimestamp":1745287505,"startTime":"0","endTime":"0","summary":"新京报讯(记者王卡拉)4月21日,京东健康与诺和诺德在北京签署战略合作协议,将携手打造肥胖症公众科普专区,助力糖尿病一站式诊疗,全面赋能慢病管理数字化转型升级。为了应对严重慢性疾病的挑战,我国将“糖尿病防治行动”列为《健康中国行动(2019-2030年)》15个专项行动之一,并持续推进《“体重管理年”活动实施方案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504223384063334.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504223384063334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","BK1142","BK4007","BK4599","BK1571","BK4588","BK4585","BK1247","NVO","LU1093756168.USD","BK1583","LU0456827905.SGD","IE00BZ1G4Q59.USD","BK1615","BK1591","IE00BKVL7J92.USD","BK1589","06618","LU0051755006.USD","BK4532","BK1515","86618","LU1093756325.SGD"],"gpt_icon":1},{"id":"2529360783","title":"白雲山(00874):明興藥業收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》","url":"https://stock-news.laohu8.com/highlight/detail?id=2529360783","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529360783?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:05","pubTimestamp":1745287500,"startTime":"0","endTime":"0","summary":"白云山(00874)发布公告,近日,该公司子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》,同意明兴药业核减生产范围、生产车间和生产线。明兴药业白云厂区已实现规模化运作。本次核减生产范围、生产车间和生产线,有利于进一步整合生产资源、优化产能布局,继续保持稳定的生产能力,满足市场需求。本次获得《药品生产许可证》,对本公司当期业绩无重大影响。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-22/doc-inetyyey7952741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK0183","600332","BK0012","BK0096","BK1197","BK1521","BK1515","BK1606","BK0188","BK0097","BK0196","BK0028","BK1191","BK0175","BK0239","00874"],"gpt_icon":0},{"id":"2529367183","title":"【港股醫藥股走強 歌禮制藥漲近18%】截至發稿,歌禮制藥-B(01672.HK)漲17.81%、榮昌生物(09995.HK)漲10.06%、映恩生物-B(09606.HK)漲9%、來凱生物-B(02105.HK)漲8.25%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529367183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529367183?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:55","pubTimestamp":1745286903,"startTime":"0","endTime":"0","summary":"截至发稿,歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22095549737746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1969619763.USD","BK1161","688331","BK1515","LU2328871848.SGD","01477","LU2148510915.USD","BK1583","01672","02105","LU1064130708.USD","LU1064131003.USD","BK1574","BK1191","159718","09995","BK0239"],"gpt_icon":0},{"id":"2529678053","title":"總規模10億元中生引領基金揭牌,浦東創投、中國生物製藥等為首關出資人","url":"https://stock-news.laohu8.com/highlight/detail?id=2529678053","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529678053?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:53","pubTimestamp":1745286791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1521","01177","399441","BK1191","161726","BK1589","BK1515"],"gpt_icon":0},{"id":"2529362752","title":"港股創新藥板塊走強,歌禮制藥(01672.HK)漲超20%,榮昌生物(09995.HK)、石藥集團(01093.HK)漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2529362752","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529362752?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:49","pubTimestamp":1745286560,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","LU0501845795.SGD","159992","688235","BK1588","LU1226287792.SGD","LU0307460666.USD","BK1583","IE0008368742.USD","LU1226288253.USD","IE00BZ08YT58.USD","BK4614","07226","09995","LU1152091754.HKD","01801","01672","HSTECH","LU1951186391.HKD","LU1993786604.SGD","BK4139","LU1152091168.USD","HSCEI","LU1226287529.USD","BK1574","01093","IE00BZ08YS42.EUR","LU1226288170.HKD","ONC","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0140636845.USD","BK1500","LU1807302812.USD","SG9999004220.SGD","06978","06160","YANG","688331","BK1521","IE00B031HY20.USD","LU2488822045.USD","LU1008478684.HKD","LU1969619763.USD","LU2328871848.SGD","IE0008369823.USD","01477","BK1515","IE00B543WZ88.USD","BK1161"],"gpt_icon":0},{"id":"2529362850","title":"港股異動 | 歌禮制藥-B(01672)早盤漲超22% 禮來公佈口服降糖藥積極結果 ASC30具備更大商業化BD潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2529362850","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529362850?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:41","pubTimestamp":1745286075,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,歌礼制药-B早盘涨超20%,截至发稿,涨20.65%,报5.96港元,成交额1900.82万港元。消息面上,4月14日,辉瑞因潜在肝损伤终止开发GLP-1小分子受体激动剂Danuglipron。4月17日,礼来宣布口服药Orforglipron的III期ACHIEVE-1研究取得积极顶线结果,在糖化血红蛋白管理、体重控制和安全性方面均与注射剂型相仿,即将申报上市。花卉粗昂证券指出,目前歌礼制药旗下ASC30是唯一一款即可以口服,又可以超长效皮下注射的小分子GLP-1药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4533","LU1551013342.USD","LU0256863902.USD","LU1720051017.SGD","IE0009355771.USD","01672","LU2552382132.HKD","LU1974910355.USD","LU2491050071.SGD","LU0097036916.USD","LU2237443978.SGD","LU0096364046.USD","LU1069344957.HKD","BK1515","LU1989771016.USD","SG9999018857.SGD","SGXZ51526630.SGD","LU0058720904.USD","IE00BK4W5L77.USD","LU2750360641.GBP","LLY","LU2237438978.USD","LU1868837136.USD","LU0466842654.USD","LU2237443895.HKD","LU1868836757.USD","LU0820561818.USD","LU2264538146.SGD","LU1551013425.SGD","LU0820561909.HKD","LU1712237335.SGD","LU2552382215.SGD","BK4599","SGXZ99366536.SGD","LU0198837287.USD","LU1988902786.USD","SG9999014914.USD","LU2491049909.HKD","LU2089984988.USD","LU2265009873.SGD","LU0289739699.SGD","LU0320765059.SGD","LU2361044865.SGD","LU2237443622.USD","LU0385154629.USD","LU1093756325.SGD","LU1232071149.USD","01477","LU0122379950.USD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2529163364","title":"年內基金業績排名生變:北交所、醫藥崛起,機器人板塊退潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2529163364","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529163364?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:36","pubTimestamp":1745285804,"startTime":"0","endTime":"0","summary":"进入二季度以来,行情遭遇调整,今年以来业绩领涨的基金榜单也发生较大变化,北交所主题基金和医药主题基金表现抢眼。东方财富Choice数据显示,截至4月21日,华夏北交所创新中小企业精选两年定开混合以62.36%的收益率暂居榜首,中信建投北交所精选两年定开混合A紧随其后,收益率达61.48%。此外,汇添富北交所创新精选两年定开混合A收益率超过50%。与北交所和医药主题基金的强势表现形成对比的是,重仓机器人概念股的基金净值出现较大回撤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.huanqiu.com/article/4MNQoOblaLW","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_huanqiu","symbols":["BK1515","09939","BK1574","BK1161"],"gpt_icon":0},{"id":"2529127362","title":"石藥集團盤中異動 早盤股價大漲5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529127362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529127362?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:33","pubTimestamp":1745285591,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时33分,石药集团股票出现异动,股价大幅拉升5.04%。截至发稿,该股报5.840港元/股,成交量1757.01万股,换手率0.15%,振幅5.04%。石药集团股票所在的药品行业中,整体涨幅为0.24%。其相关个股中,三生制药、远大医药、先声药业涨幅较大,振幅较大的相关个股有先声药业、远大医药、石药集团,振幅分别为5.22%、5.22%、4.86%。石药集团公司简介:石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093311973ff7b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093311973ff7b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","LU0326950275.SGD","LU1226287792.SGD","SG9999004220.SGD","BK1521","01093","IE0008368742.USD","IE00B031HY20.USD","BK1191","IE00BZ08YR35.GBP","LU1993786604.SGD","LU1226288170.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1152091168.USD","LU0072913022.USD","LU1226288253.USD","IE00BZ08YT58.USD","LU1960683339.HKD","BK1515","IE00B543WZ88.USD","LU0140636845.USD","LU1951186391.HKD","LU1152091754.HKD","LU1226287529.USD","LU1008478684.HKD","LU0067412154.USD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1807302812.USD"],"gpt_icon":0},{"id":"2529624843","title":"東陽光長江藥業盤中異動 股價大漲5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529624843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529624843?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:32","pubTimestamp":1745285557,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时32分,东阳光长江药业股票出现波动,股价快速拉升5.04%。截至发稿,该股报12.500港元/股,成交量190.34万股,换手率0.29%,振幅4.71%。东阳光长江药业股票所在的药品行业中,整体涨幅为0.25%。其相关个股中,远大医药、三生制药、信达生物涨幅较大,振幅较大的相关个股有远大医药、先声药业、东阳光长江药业,振幅分别为5.22%、4.83%、4.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093237973ff77f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093237973ff77f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2529433362","title":"歌禮制藥-B股價拉昇16.40% 市值漲8.95億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529433362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529433362?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 09:32","pubTimestamp":1745285522,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时32分,歌礼制药-B股票出现波动,股价大幅拉升16.40%。截至发稿,该股报5.750港元/股,成交量141.8万股,换手率0.15%,振幅8.70%。资金方面,该股资金流入238.68万港元,流出375.936万港元。歌礼制药-B股票所在的生物技术行业中,整体涨幅为0.57%。其相关个股中,歌礼制药-B、来凯医药-B、荣昌生物涨幅较大,振幅较大的相关个股有博安生物、来凯医药-B、歌礼制药-B,振幅分别为10.76%、9.95%、8.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042209320294dd6f77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042209320294dd6f77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1574","BK1515","01477","BK1161","BK1191"],"gpt_icon":0},{"id":"2529636626","title":"北京大學全球健康發展研究院院長劉國恩:分級診療任重道遠","url":"https://stock-news.laohu8.com/highlight/detail?id=2529636626","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529636626?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 08:48","pubTimestamp":1745282880,"startTime":"0","endTime":"0","summary":" 在医疗方面,更好地推进分级诊疗是我国医改的首要目标。 近日,《瞭望东方周刊》就分级诊疗体系建设、医保制度改革、创新药发展等问题专访了中国医学科学院学部委员,北京大学全球健康发展研究院院长、国家发展研究院北大博雅特聘教授刘国恩。这就说明引导普通门诊患者流向基层医疗的“分级诊疗”,还任重道远。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2025-04-22/doc-inetyyey7914719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09939","BK1515","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":2,"totalSize":417,"code":"91000000","status":"200"}]}}